Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease-The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic.

Nationwide Cross-Sectional Analysis of Mortality Trends in Patients with Sarcoidosis and Non-Ischemic Cardiovascular Disease-The Impact of Gender, Ethnicity, Geographical Location, and COVID-19 Pandemic.

Publication date: Dec 08, 2024

Background and Objectives: The epidemiological data regarding mortality rates of adults with sarcoidosis and non-ischemic cardiovascular disease (CVD) are limited. A retrospective observational analysis was conducted to identify trends and disparities related to sarcoidosis and non-ischemic cardiovascular disease mortality among the adult US population from 1999 to 2022. Methods: We used the Centers for Disease Control and Prevention (CDC) WONDER database to extract death certificate data for the adult US population (≥25 years). The age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and annual percent changes (APCs) were determined using Joinpoint. Results: Between 1999 and 2022, 23,642 deaths were identified related to non-ischemic CVD + sarcoidosis. The overall AAMR increased from 0. 2 (95% CI, 0. 2 to 0. 3) in 1999 to 0. 5 (95% CI, 0. 5 to 0. 6) in 2022. Females had a higher AAMR than males (0. 6 vs. 0. 5). Non-Hispanic (NH) blacks had the highest AAMR, followed by NH whites and Hispanic or Latinos. The southern region had the highest AAMR (0. 7: 95% CI, 0. 6-0. 7), followed by the Midwest (0. 6, 95% CI, 0. 54-0. 669), the Northeast (0. 5, 95% CI, 0. 5 to 0. 6), and the West (0. 4; 95% CI, 0. 3-0. 4). Urban and rural areas had comparable mortality rates (0. 5 vs. 0. 6). People aged 65+ had the highest AAMRs. Conclusions: The overall mortality rates for non-ischemic CVD and sarcoidosis have increased in the US from 1999 to 2022. Females and NH blacks had higher AAMRs, while a minimal variation was observed based on geographical regions. Early diagnosis and prompt management are the keys to reducing the mortality burden of non-ischemic CVD plus sarcoidosis.

Open Access PDF

Concepts Keywords
Females cardiovascular disease
Latinos COVID-19
Midwest ethnicity
Pandemic gender
geographic location
sarcoidosis

Semantics

Type Source Name
disease MESH Sarcoidosis
disease MESH Cardiovascular Disease
disease MESH COVID-19 Pandemic
disease MESH death
drug DRUGBANK Coenzyme M
disease MESH heart failure
disease MESH cardiac arrest
disease MESH atrioventricular blocks
disease IDO blood
disease MESH obesity
disease MESH hyperlipidemia
disease MESH ischemic heart diseases
drug DRUGBANK Methionine
disease MESH inflammation
disease MESH scarring
disease MESH infection
disease MESH granuloma
disease MESH autoimmune diseases
drug DRUGBANK Flunarizine
disease MESH unemployment
disease IDO country
disease MESH complications
disease MESH morbidity
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Sudden Death
drug DRUGBANK Elm
disease MESH cancer
disease MESH Rheumatic Diseases
disease MESH Musculoskeletal Diseases
disease MESH Myocarditis
disease IDO susceptibility
drug DRUGBANK Medical air
pathway REACTOME Release
disease MESH Pulmonary Sarcoidosis

Original Article

(Visited 1 times, 1 visits today)